Physician profile
Lev Yagudayev
NPI 1881885432
$2,290.59
in general payments reported to CMS, 2019-2025
23 companies · $331 in 2025
The $331 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $820 · 2020: $105 · 2021: $239 · 2022: $216 · 2023: $256 · 2024: $323 · 2025: $331.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $910.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $910.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $364.65 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $250.00 | 2024-2025 | Jardiance |
| Novo Nordisk INC | $245.00 | 2021-2022 | |
| Atricure, INC. | $178.18 | 2022-2023 | |
| Genzyme Corporation | $150.00 | 2025 | |
| Revance Therapeutics, INC. | $148.90 | 2024 | Daxxify |
| Amgen INC. | $147.30 | 2019 | |
| Dermira, INC. | $125.00 | 2019 | |
| Corcept Therapeutics | $124.34 | 2019 | |
| Intuity Medical INC | $101.87 | 2023 | Pogo Automatic Blood Glucose Monitoring System |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $100.00 | 2019 | |
| Leo Pharma INC. | $72.34 | 2023-2024 | Adbry |
| Organon LLC | $56.29 | 2025 | Vtama |
| Novartis Pharmaceuticals Corporation | $47.37 | 2019 | |
| Mylan Specialty L.P. | $28.38 | 2023 | Yupelri |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $23.85 | 2019 | |
| Almirall LLC | $23.47 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.00 | 2019 | |
| Vyne Pharmaceuticals INC. | $19.30 | 2020 | |
| Sanofi-Aventis U.S. LLC | $18.84 | 2019 | |
| Abbvie INC. | $16.50 | 2020 | |
| Dermavant Sciences, INC. | $14.78 | 2023 | Vtama |
| Janssen Pharmaceuticals, INC | $14.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lev Yagudayev listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.